Ensysce Biosciences (ENSC) Competitors

Ensysce Biosciences (NASDAQ:ENSC) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Do institutionals & insiders have more ownership in ENSC or OVID?

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 7.9% of Ensysce Biosciences shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, ENSC or OVID?

Ensysce Biosciences has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.

Do analysts recommend ENSC or OVID?

Ovid Therapeutics has a consensus price target of $3.03, suggesting a potential upside of 961.72%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ovid Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is ENSC or OVID more profitable?

Ensysce Biosciences has a net margin of -179.26% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-179.26%	-292.81%	-158.83%
Ovid Therapeutics	-5,142.56%	-39.24%	-26.19%

Does the MarketBeat Community favor ENSC or OVID?

Ovid Therapeutics received 355 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 71.03% of users gave Ovid Therapeutics an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.

Company	Underperform	Outperform
Ensysce Biosciences	Outperform Votes 3 60.00%	Underperform Votes 2 40.00%
Ovid Therapeutics	Outperform Votes 358 71.03%	Underperform Votes 146 28.97%

Which has higher valuation & earnings, ENSC or OVID?

Ensysce Biosciences has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$2.23M	2.37	-$10.61M	-$6.54	-0.34
Ovid Therapeutics	$548K	37.07	-$52.34M	-$0.35	-0.82

Does the media favor ENSC or OVID?

In the previous week, Ovid Therapeutics had 12 more articles in the media than Ensysce Biosciences. MarketBeat recorded 16 mentions for Ovid Therapeutics and 4 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.78 beat Ovid Therapeutics' score of 0.53 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ensysce Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ovid Therapeutics beats Ensysce Biosciences on 13 of the 19 factors compared between the two stocks.